Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

• Research unit: INNOSUISSE
• Project number: 59256.1 IP-LS

Short description (German)

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Short description (English)

Defining the pharmacology, safety, and dosing of #PB-FC# a novel bacterial drug-candidate for reversal of dysbiosis in acute graft-versus-host disease

Abstract (German)

In this project PharmaBiome#s Functional Consortium (PB-FC) designed for the treatment of gut dysbiosis in acute graft-versus-host disease (aGvHD) patients will be tested in mouse models to answer essential questions for the successful translation of our novel, function-based approach.